Reaction mass of 1-chlorodecane and 1-chlorododecane

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1982

Report date:

1982

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EPA OPP 81-1 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

no

Remarks:

study performed prior to implementation of GLP

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1-chlorodecane; 1-chlorododecane

EC Number:

907-241-9

Molecular formula:

C10H21Cl and C12H25Cl

IUPAC Name:

1-chlorodecane; 1-chlorododecane

Test material form:

other: liquid

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: 6-8 weeks
- Weight at study initiation: males 157-202 g, females 152-192 g
- Fasting period before study: overnight
- Housing: 5 animals/cage
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 1 week

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C +/- 2°C
- Humidity (%): 55% +/- 10%
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 31.08.1981 To: 17.12.1981

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

polyethylene glycol

Details on oral exposure:

Single oral intubation via gavage to animals fasted overnight.
A dilution of the test compound was prepared with the help of a homogenizer (Ultra-Turrax) and kept stable during treatment with a magnetic stirrer. In the doses above 5000 mg/kg bw the test item was applied as a concentrate.

Doses:

500, 3000, 5000, 10000 and 20000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations: at 1, 2, 3, 5 and 24 h after dosing and once daily thereafter
- Frequency of weighing: day 0 (prior to dosing), day 7 and day 14
- Necropsy of survivors performed: yes

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 20 000 mg/kg bw

Based on:

test mat.

Mortality:

During the study period no mortality was observed.

Clinical signs:

other: The main symptoms observed were: sedation, dyspnoea, exophthalmos, curved position, diarrhoea and ruffled fur.

Gross pathology:

No pathological organ changes were observed.

Applicant's summary and conclusion

Interpretation of results:

study cannot be used for classification

Remarks:

Migrated information

Conclusions:

The acute oral LD50 of the test item in rats of both sexes observed over a period of 14 days was estimated to be greater than 20.000 mg/kg bw.